[Ocular hypotonia in leukemia].
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077404:Cidofovir; D003596:Cytosine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D015448:Leukemia, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000175:diagnosis*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000175:diagnosis*
D000970:Antineoplastic Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir
Hypotonia bulbi bei Leukämie.